Q1 2017 13F Holders as of 31 Mar 2017
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
236,234,693
-
Total 13F shares
-
20,825,309
-
Share change
-
+2,623,919
-
Total reported value
-
$191,436,543
-
Put/Call ratio
-
23%
-
Price per share
-
$9.20
-
Number of holders
-
86
-
Value change
-
+$23,185,087
-
Number of buys
-
38
-
Number of sells
-
43
Institutional Holders of Akebia Therapeutics, Inc. - Common Stock (AKBA) as of Q1 2017
As of 31 Mar 2017,
Akebia Therapeutics, Inc. - Common Stock (AKBA) was held by
86 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
20,825,309 shares.
The largest 10 holders included
EAGLE ASSET MANAGEMENT INC, BlackRock Inc., Nantahala Capital Management, LLC, VANGUARD GROUP INC, Novo A/S, FIRST MANHATTAN CO, FMR LLC, MORGAN STANLEY, Marshall Wace North America L.P., and STATE STREET CORP.
This page lists
86
institutional shareholders reporting positions in this security
for the Q1 2017 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.